- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03630991
Edetato cálcico disódico o succímero en el tratamiento de pacientes con leucemia mieloide aguda o síndrome mielodisplásico sometidos a quimioterapia
Monitoreo, desintoxicación y reequilibrio de metales durante la terapia de leucemia mieloide aguda (AML) y síndrome mielodisplásico (MDS)
This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to lower the level of metals found in the bone marrow and blood and may help to control the disease and/or improve response to chemotherapy.
Descripción general del estudio
Estado
Condiciones
- Leucemia mieloide aguda
- Leucemia mieloide aguda derivada de un síndrome mielodisplásico previo
- Leucemia mieloide aguda secundaria
- Síndrome mielodisplásico
- Leucemia mieloide aguda recurrente
- Síndrome mielodisplásico recurrente
- Leucemia mieloide aguda refractaria
- Síndrome mielodisplásico refractario
- Síndrome mielodisplásico de alto riesgo
- Leucemia mielógena crónica en fase blástica, BCR-ABL1 positivo
- Leucemia mielógena crónica recurrente, BCR-ABL1 positivo
- Leucemia mielógena crónica refractaria, BCR-ABL1 positivo
- Neoplasia mieloproliferativa
- Neoplasia mielodisplásica/mieloproliferativa
- Síndrome mielodisplásico secundario
- Leucemia mielógena crónica, BCR-ABL1 positivo
- Neoplasia mielodisplásica/mieloproliferativa recurrente
- Síndrome mielodisplásico de muy alto riesgo
Intervención / Tratamiento
Descripción detallada
PRIMARY OBJECTIVES:
- To establish the maximal tolerated dose (MTD) of Phase 1 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients undergoing therapy combined with succimer (DMSA) and edetate calcium disodium (Ca-EDTA). (Phase I dose escalation)
- To assess the efficacy information regarding the combined therapy in terms of the overall response rate (ORR) including complete remission (CR), CR with partial hematological recovery (CRh), CR with incomplete count recovery (CRi), morphologic leukemia free state (MLFS), and partial remission (PR). (Phase I expansion)
SECONDARY OBJECTIVES:
- To assess the complete remission (CR), complete remission with incomplete hematologic recovery (CRi), complete remission with partial hematological recovery (CRh), partial remission (PR), hematologic improvement (HI), morphologic leukemia free state (MLFS) rates, cytogenetic response, and the 1-year overall survival (OS) in AML patients and the CR/marrow CR/hematologic improvement (HI) rate, partial remission (PR) rate and 1-year overall survival (OS) and cytogenetic response in MDS patients undergoing MDS/AML therapy combined with DMSA and Ca-EDTA.
- To assess overall survival and event free survival in AML and MDS patients undergoing AML and MDS therapy combined with DMSA and Ca-EDTA
- To assess remission duration in AML and MDS patients undergoing AML and MDS therapy combined with DMSA and Ca-EDTA.
- To monitor toxic and essential metal levels during AML and MDS therapy combined with DMSA and Ca-EDTA and to evaluate the reduction in metals in the bone marrow and blood of newly diagnosed AML and MDS patients undergoing metal detoxification combined with standard AML/MDS therapy.
- To evaluate the safety profile in AML and MDS patients undergoing AML and MDS therapy combined with DMSA and Ca-EDTA.
- Correlate metal and copper isotopic abundance ratios of AML and MDS patients with clinical data, conventional cytogenetics, extensive next generation sequencing (NGS) (300-gene panel), exposure survey data, and clinical outcome data, and to perform a larger analysis by pooling this data with metal/genomic/survey/outcome data obtained on 2017-0937 and PA15-0302.
- Estimate the progression rate in MDS patients.
- To assess other responses of interest.
- To compare overall survival and response in this study with historical data of patients who were treated without Ca-EDTA and DMSA.
EXPLORATORY OBJECTIVES:
- To correlate the degree of metal chelation with the degree of therapeutic response and minimal residual disease (MRD).
- To collect environmental exposure data on the environmental health assessment survey.
- To assess P53 folding or p53 activity before and after the first dose of Ca-EDTA chelation in MDS and AML patients, and patients with other malignancies.
- To study changes in cytogenetic/molecular data during treatment, as well as, protein expression data (by immunohistochemistry or proteomics), including for transcription factors/tumor suppressors (e.g. TP53 and MYC).
- To perform pre-clinical proof of concept studies of metals and metal chelators in a variety of AML cells and cell lines including: AML cell lines, primary hematologic malignancy cells, stromal cell lines, and patient-derived stromal cells.
- To explore metal chelation in pediatric, adolescent, and young adult cancer patients.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Maro Ohanian
- Número de teléfono: 713-792-2631
- Correo electrónico: mohanian@mdanderson.org
Ubicaciones de estudio
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- M D Anderson Cancer Center
-
Contacto:
- Maro Ohanian
- Número de teléfono: 713-792-2631
- Correo electrónico: mohanian@mdanderson.org
-
Investigador principal:
- Maro Ohanian
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients ≥18 years of age, or their legally authorized representative (LAR), must have the ability to understand the requirements of the study and must voluntarily sign the informed consent form. For patients <18 years of age, a parent or LAR must have the ability to understand the requirements of the study and must voluntarily sign the informed consent form. Any required verbal assent and/or signed assent of minor must be obtained for participants <18 years.
- Age ≥18 years at the time of signing the informed consent form.
- Age ≥1 years and <18 years with weight requirement ≥8 kg at the time of the signing of the informed consent form (e.g. by parent or LAR)
- Patients enrolling in the pediatric/adolescent/young adult exploratory cohort must be:
Age ≥ 1 years and <18 years with weight requirement ≥8 kg at the time of the signing of the informed consent form (e.g. by parent or LAR), Or age 18 years -39 years at the time of the signing of the informed consent form
- Diagnosis of any of the following:
- Newly diagnosed (or untreated) AML with intermediate-risk/poor-risk cytogenetics, intermediate-risk/poor-risk molecular, or secondary AML (i.e. therapy-related or evolved from antecedent hematologic malignancy)
- Newly diagnosed (or untreated) myeloid blast phase of myeloproliferative neoplasm (MPN) (including myeloid blast phase of chronic myeloid leukemia [CML])
- Newly diagnosed (or untreated) high-risk, very-high risk or secondary MDS/myeloid neoplasm
- Newly diagnosed (or untreated) MDS/MPN (regardless of cytogenetic/molecular status)
- Relapsed and/or refractory AML, MDS/myeloid neoplasm , MDS/MPN, myeloid blast phase of MPN (including myeloid blast phase of CML)
- Patients enrolling in the childhood/adolescent/young adult exploratory cohort may have any of the following diagnoses:
- High-risk or relapsed/refractory childhood, adolescent, or young adult malignancies including but not limited to high-risk or relapsed/refractory ALL or other high-risk or relapsed refractory malignancies
- This includes, but is not limited to, the following: High-risk ALL/LL including T-ALL/LL, Ph-like ALL/LL, Ph+ B-ALL/LL, B-ALL/LL with CNS lymphoid leukemic involvement, testicular involvement, other extramedullary involvement by ALL/LL; ALL/LL with any of the NCI high-risk features: patients aged 10 years or older and those with a white blood cell count ≥50 × 109 per L), high-risk cytogenetics (MLL rearrangements, near haploidy [<30 chromosomes], low hypodiploidy [30-39 chromosomes], t[17;19][q23;p13], intrachromosomal amplification of chromosome 21), Burkitts'; Burkitt's-like, Double-Hitt; CNS involvement by any non-primary brain malignancy; Metastatic disease of any malignancy; 5-year survival prognosis of less than 50%, based on the treating physician's assessment
- Patients on non-investigational regimens or on IND-exempt MD Anderson studies (for hematologic malignancies) of approved drugs are also eligible.
- Patients on IND studies (for hematologic malignancies) utilizing FDA approved commercially available drugs are eligible.
- Investigational agents that are not used for treatment of the leukemia per se (e.g. anti-infective prophylaxis or therapy) will be allowed. Other supportive care studies are allowed, even if under an IND.
- Newly diagnosed MDS or AML, as well as MDS/MPN, myeloid blast phase of MPN (including myeloid blast phase of CML), patients can enroll on this study after start of non-investigational induction therapy, but must be within first 3 cycles of therapy of front-line therapy. Patients with relapsed and/or refractory AML, MDS, MDS/MPN, myeloid blast phase of MPN (including myeloid blast phase of CML) can enroll. Newly diagnosed patients enrolling in the exploratory cohort with high-risk malignancies can enroll after the start of non-investigational therapy but must be within first 3 cycles of front-line therapy.
- Transformed and untreated AML transformed from previously treated MDS, myeloproliferative neoplasm (MPN) or other types of secondary AML are allowed. Myeloid-Blast Phase of MPN and Chronic Myeloid Leukemia (CML) are allowed.
- Eastern Cooperative Oncology Group (ECOG) performance status of =< 3 or Lansky or Karnofsky ≥ 30 at study entry; patients who are unable to walk, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
- Laboratory test results within these ranges (unless due to leukemia or other hematologic malignancy):
- Serum creatinine =< 1.5 mg/dL
- Total Bilirubin =< 2.0 x upper limit of normal (ULN), unless the patient has Gilbert's
- AST (SGOT) and/or ALT (SGPT) =< 2.0 x ULN
- Women of childbearing potential (WCBP) must have a negative urine pregnancy test within 7 days and must either commit to continued abstinence from heterosexual intercourse or adopting at least one highly effective method of contraception. These methods include intra-uterine device, tubal ligation, partner's vasectomy, and hormonal birth control pills. Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential
- Extramedullary disease is allowed as long as it can be measured and followed for response.
Note: Patients can be considered MDS by either WHO or FAB150 criteria Note: MDS risk status assessment is based on IPSS-R and/or IPSS-M. AML risk status assessment is based on ELN and World Health Organization classification
Exclusion Criteria:
- Nursing and pregnant females. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Uncontrolled inter-current illness including, but not limited to, uncontrolled active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements or which judged by the investigator, places the patient at unacceptable risk
- Acute Promyelocytic leukemia (APL)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Cohort I (edetate calcium disodium, multivitamin)
During standard of care chemotherapy, patients receive edetate calcium disodium IV daily over 30 minutes for 4 doses for each cycle. Treatment continues for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive up to 12 multivitamin capsules PO daily while on study. DOSE EXPANSION: During standard of care chemotherapy, patients receive edetate calcium disodium IV daily over 30 minutes for 4 doses for each cycle. DMSA daily for 21 days. Multivitamin capsules daily while on study. Patients will receive treatment for up to 6 cycles in the absence of disease progression or unacceptable toxicity. |
Given IV
Otros nombres:
Given PO
Otros nombres:
|
|
Experimental: Cohort II (succimer, multivitamin)
During standard of care chemotherapy, patients receive succimer PO daily for 8 or 21 days of each cycle beginning day 1. Treatment continues for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive up to 12 multivitamin capsules PO daily while on study. DOSE EXPANSION: During standard of care chemotherapy, patients receive edetate calcium disodium IV daily over 30 minutes for 4 doses for each cycle. DMSA daily for 21 days. Multivitamin capsules daily while on study. Patients will receive treatment for up to 6 cycles in the absence of disease progression or unacceptable toxicity. |
Given PO
Otros nombres:
Given PO
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of adverse events
Periodo de tiempo: At 30 days post-treatment
|
Safety data of the patients will be summarized using descriptive statistics such as mean, standard deviation, median and range. Will follow standard reporting guidelines for adverse events. Safety data will be summarized by category, severity and frequency. |
At 30 days post-treatment
|
|
Maximum tolerated doses (MTD) of edetate calcium disodium (Ca-EDTA) and succimer (DMSA) (Phase 1 dose escalation)
Periodo de tiempo: Up to the end of cycle 1 (each cycle is 28 days)
|
The MTD is the highest dose level in which < 2 patients of 6 develop first cycle dose-limiting toxicity (DLT). |
Up to the end of cycle 1 (each cycle is 28 days)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Maro Ohanian, M.D. Anderson Cancer Center
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Neoplasias
- Enfermedad crónica
- Atributos de la enfermedad
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Procesos Neoplásicos
- Leucemia Mieloide
- Enfermedades de la médula ósea
- Leucemia
- Transformación Celular Neoplásica
- Carcinogénesis
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades hemic y linfáticas
- Leucemia Mieloide Aguda
- Síndromes mielodisplásicos
- Trastornos mieloproliferativos
- Enfermedades mielodisplásicas-mieloproliferativas
- Leucemia, Mielógena, Crónica, BCR-ABL Positivo
- Crisis explosiva
- Compuestos de azufre
- Químicos orgánicos
- Ácidos, acíclico
- Ácidos carboxílicos
- Amina
- Acetato
- Compuestos de sulfhidrilo
- Etilendiaminas
- Diamina
- Poliamina
- Ácidos dicarboxílicos
- Succinatos
- Ácido edético
- Ácido pentético
- Succimer
- Geritol
Otros números de identificación del estudio
- 2017-0752
- 2017-0752 (Otro identificador: M D Anderson Cancer Center)
- NCI-2018-01610 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .